GREENLION Project: Advanced Manufacturing Processes for Low Cost Greener Li-Ion Batteries

GREENLION is a Large Scale Collaborative Project within the FP7 (GC.NMP.2011-1) leading to the manufacturing of greener and cheaper Li-Ion batteries for electric vehicle applications via the use of water soluble, fluorine-free, high thermally stable binders, which would eliminate the use of VOCs and reduce the cell assembly cost. The project has 6 key objectives: (i) development of new active and inactive battery materials viable for water processes (green chemistry); (ii) development of innovative processes (coating from aqueous slurries) capable of reducing electrode production cost and avoid environmental pollution; (iii) development of new assembly procedures (including laser cutting and high temperature pre-treatment) capable of substantially reduce the time and the cost of cell fabrication; (iv) lighter battery modules with easier disassembly through eco-designed bonding techniques; (v) waste reduction, which, by making use of the watersolubility of the binder, allows the extensive recovery of the active and inactive battery materials; and (vi) development of automated process and construction of fully integrated battery module for electric vehicle applications with optimized electrodes, cells, and other ancillaries. Achievements during the first 18 months of the project, especially on materials development and water-based electrode fabri cation are reported herein

Flavour-changing top decays in the aligned two-Higgs-doublet model

We perform a complete one-loop computation of the two-body flavour-changing top decays t --> ch and t --> cV (V = gamma, Z), within the aligned two-Higgs-doublet model. We evaluate the impact of the model parameters on the associated branching ratios, taking into account constraints from flavour data and measurements of the Higgs properties. Assuming that the 125 GeV Higgs corresponds to the lightest CP-even scalar of the CP-conserving aligned two-Higgs-doublet model, we find that the rates for such flavour-changing top decays lie below the expected sensitivity of the future high-luminosity phase of the LHC. Measurements of the Higgs signal strength in the di-photon channel are found to play an important role in limiting the size of the t --> ch decay rate when the charged scalar of the model is light

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. Patients and methods: Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. Results: Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade 653 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). Conclusions: Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design